This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
MRTX Aperçu des actions
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Mirati Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$58.70 |
| Plus haut sur 52 semaines | US$64.41 |
| Plus bas sur 52 semaines | US$27.30 |
| Bêta | 0.77 |
| 1Variation sur 1 mois | -0.41% |
| Variation sur 3 mois | 6.32% |
| Variation sur 1 an | 18.92% |
| 3Variation sur 3 ans | -71.20% |
| Variation sur 5 ans | -5.55% |
| Évolution depuis l'introduction en bourse | 590.59% |
Nouvelles et mises à jour récentes
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Rendement pour les actionnaires
| MRTX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -0.5% | -2.9% | 0.9% |
| 1Y | 18.9% | 18.9% | 32.3% |
Rendement vs Industrie: MRTX exceeded the US Biotechs industry which returned 6.9% over the past year.
Rendement vs marché: MRTX matched the US Market which returned 19.4% over the past year.
Volatilité des prix
| MRTX volatility | |
|---|---|
| MRTX Average Weekly Movement | 1.0% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: MRTX has not had significant price volatility in the past 3 months.
Volatilité au fil du temps: MRTX's weekly volatility has decreased from 10% to 1% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1995 | 587 | Chuck Baum | www.mirati.com |
Mirati Therapeutics, Inc. Résumé des fondamentaux
| MRTX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$4.12b |
| Bénéfices(TTM) | -US$725.88m |
| Recettes(TTM) | US$38.19m |
107.8x
Ratio P/S-5.7x
Ratio P/ELe site MRTX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MRTX compte de résultat (TTM) | |
|---|---|
| Recettes | US$38.19m |
| Coût des recettes | US$510.48m |
| Marge brute | -US$472.29m |
| Autres dépenses | US$253.59m |
| Les revenus | -US$725.88m |
Derniers bénéfices déclarés
Sep 30, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -10.35 |
| Marge brute | -1,236.66% |
| Marge bénéficiaire nette | -1,900.65% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de MRTX?
Voir les performances historiques et les comparaisons